Pharmaceutical giant GSK is relocating its research centre to Cambridge with a £400 million investment, bringing long-awaited positive momentum to the company and a boost to the UK's life sciences sector.

The move represents a significant endorsement of Britain's scientific capabilities, with Andy Burnham hailing it as a "vote of confidence" in the country. GSK's decision comes with encouraging news for shareholders and signals the company's commitment to cutting-edge research in one of Europe's leading biotech hubs. Read the full story →

Today's takeaway: Major corporate investment in UK research facilities shows innovation remains an attractive bet despite economic headwinds.